Recent Finacing
Recent Raise
BioXell develops urological and inflammatory treatments via a proprietary Vitamin D3 analogue platform; lead candidate BXL628 is in Phase II, with programs for overactive bladder, prostatitis, anti‑TrKA antibody, GPCR/TREM research.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
